All translations

Enter a message name below to show all available translations.

Found 2 translations.

Name	Current message text
^h English (en)	Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing losartan by [[Sandoz]], [[Torrent Pharmaceuticals]], [[Hetero Drugs\|Hetero Labs]], Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, [[Teva Pharmaceutical Industries\|Teva Pharmaceuticals]], [[Vivimed Labs\|Vivimed Life Sciences]], and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens [[N-nitrosodiethylamine]], N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the [[Active ingredient\|active pharmaceutical ingredient]] (API).
^h Japanese (ja)	2018年11月から2019年9月にかけて、FDAは[[Wikipedia:Sandoz\|Sandoz]]、[[Wikipedia:Torrent Pharmaceuticals\|Torrent Pharmaceuticals]]、[[:en:Hetero Drugs\|Hetero Labs]]、Camber Pharmaceuticals、Legacy Pharmaceutical Packaging、[[Teva Pharmaceutical Industries\|Teva Pharmaceuticals]]によるロサルタンを含む錠剤の複数のリコールを発表した、 [[:en:Vivimed Labs\|Vivimed Life Sciences]]、およびMacleods Pharmaceutical Limitedは、[[Active ingredient/ja\|医薬品有効成分]]（API）から発がん性物質である可能性のある[[N-nitrosodiethylamine/ja\|N-ニトロソジエチルアミン]]、N-メチルニトロソ酪酸、N-ニトロソ-N-メチル-4-アミノ酪酸のいずれかが検出されたためである。